Alaunos Therapeutics
TCRT
122 hedge funds and large institutions have $356M invested in Alaunos Therapeutics in 2017 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 34 increasing their positions, 31 reducing their positions, and 11 closing their positions.
10% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 31
9% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 11
0% more funds holding
Funds holding: 122 → 122 (0)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.01% less ownership
Funds ownership: 0.28% → 0.27% (-0.01%)
5% less capital invested
Capital invested by funds: $376M → $356M (-$19.9M)
47% less call options, than puts
Call options by funds: $4.96M | Put options by funds: $9.29M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$2.71M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.91M |
| 3 |
Group One Trading
Chicago,
Illinois
|
+$841K |
| 4 |
Goldman Sachs
New York
|
+$794K |
| 5 |
D.E. Shaw & Co
New York
|
+$737K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$16.2M |
| 2 |
ARTA
A.R.T. Advisors
New York
|
-$2.05M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1.41M |
| 4 |
State Street
Boston,
Massachusetts
|
-$709K |
| 5 |
Canada Pension Plan Investment Board
Toronto Ontario,
Ontario, Canada
|
-$686K |
TCRT Hedge Fund Activity: Q3 2017 in Review
122 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Alaunos Therapeutics (TCRT) for Q3 2017, worth a combined $356M — down 5.3% from $376M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new TCRT positions and 11 closed out — a net gain of 1 holder — while 34 added to existing stakes and 31 trimmed.
The largest buyer was BlackRock, adding an estimated $2.71M. The largest seller was Susquehanna International Group, cutting an estimated $16.2M.
- 122 institutional investors held Alaunos Therapeutics (TCRT) as of Q3 2017, unchanged from Q2 2017.
- Funds reported $356M of Alaunos Therapeutics stock for Q3 2017, down 5.3% quarter-over-quarter.
- 12 funds opened new Alaunos Therapeutics positions in Q3 2017 and 11 closed out, a net change of +1 holder.
- The largest Alaunos Therapeutics buyer in Q3 2017 was BlackRock, an estimated $2.71M added.
- The largest Alaunos Therapeutics seller in Q3 2017 was Susquehanna International Group, an estimated $16.2M sold.
Based on aggregated 13F filings for Q3 2017.